ACT Capital's Unconventional Move: Acquiring TG Therapeutics Shares at a Value Gap Despite 30% Doubt

ACT Capital Management's Strategic Investment in TG Therapeutics

On February 17, 2026, ACT Capital Management announced a new investment in TG Therapeutics, acquiring 268,875 shares valued at $8,015,164. This purchase accounts for 6.5% of the fund’s $123.67 million in U.S. equity holdings at the end of the year, making TG Therapeutics the fifth-largest position in ACT’s portfolio.

This investment comes at a time when TG Therapeutics’ stock has faced significant downward pressure, closing at $28.58 on Monday—a drop of about 30% over the past year, sharply underperforming the broader market’s 18% gain. Such a move is a bold, contrarian bet: ACT Capital is allocating a substantial portion of its portfolio to a company that has recently disappointed investors.

ACT’s decision raises a pivotal question: does the current share price, which reflects deep market skepticism, undervalue the company’s true business potential? The investment thesis centers on the belief that TG Therapeutics’ strong position in commercializing treatments for B-cell malignancies and autoimmune diseases is not fully recognized by the market. This scenario is typical of situations where short-term pessimism may obscure the company’s long-term growth prospects, especially if it can deliver on its strategic goals.

TG Therapeutics: Assessing the Competitive Edge

Value investors often seek companies with a lasting competitive advantage, or “moat,” that can sustain profitability over time. TG Therapeutics operates in the specialized field of therapies for B-cell cancers and autoimmune disorders—areas with significant unmet medical needs, which can provide a strong foundation for a defensible market position. The company’s business revolves around the commercialization of proprietary drugs, most notably BRIUMVI.

The strength of TG Therapeutics’ moat depends on both its execution and the breadth of its drug pipeline. Recent financial results highlight a shift toward robust commercial operations: BRIUMVI generated $606.9 million in sales in 2025, nearly double the previous year, pushing total annual revenue to $616.3 million. Despite this impressive growth, the stock’s 30% decline signals market doubts about the sustainability of these gains, possibly due to competitive threats or concerns about future growth.

Beyond BRIUMVI, TG Therapeutics is developing a range of monoclonal antibodies and targeted therapies, such as umbralisib for B-cell cancers. This diversified pipeline is crucial for future growth, as it aims to address additional unmet needs and expand the company’s reach. ACT Capital’s investment, alongside stakes in other innovative biotech firms like Abivax and Krystal Biotech, reflects a calculated risk on companies with the potential for significant breakthroughs. In essence, ACT is not just investing in current revenues but is betting on TG Therapeutics’ ability to innovate and maintain a technological lead in a competitive industry.

In summary, TG Therapeutics’ competitive advantage is evolving. While currently anchored by a rapidly growing product, its future depends on successful pipeline development and commercialization. The market’s current valuation may be discounting this transition, presenting an opportunity for investors who believe in the company’s long-term prospects.

Valuation and the Case for Long-Term Growth

When evaluating a company like TG Therapeutics, value investors must look beyond current earnings and focus on future potential. With a market capitalization of $4.6 billion, TG Therapeutics is valued not just on present profits, but on the anticipated success of its drug pipeline. The investment rationale is essentially a wager on the company’s ability to bring new therapies to market, with the current low share price offering a favorable risk-reward profile.

A key risk for TG Therapeutics is its ongoing need for capital to support clinical trials and commercial expansion. As the company grows, it may need to raise additional funds, potentially diluting existing shareholders’ stakes. The recent 30% stock decline could reflect investor concerns about future fundraising at unattractive prices, which would erode current equity value.

The long-term growth story depends on two critical factors: successful drug development and prudent financial management. TG Therapeutics must advance its pipeline to approval and commercialization while avoiding excessive cash burn that could force dilutive capital raises. The current valuation reflects a high degree of skepticism, so the company must deliver both clinical and financial results to justify a higher share price.

ACT Capital’s investment is a classic example of a high-risk, high-reward strategy. Rather than buying a company trading below book value, the fund is investing in the potential for future profits. The willingness to accept volatility and uncertainty is balanced by the possibility of substantial long-term gains if TG Therapeutics can deliver on its promise. The fund’s significant position suggests confidence in the company’s eventual success.

Key Catalysts, Risks, and Monitoring Points

For investors seeking value, the journey from a depressed share price to realized gains hinges on specific milestones. For TG Therapeutics, the most important near-term catalysts are clinical trial results for its leading drug candidates. Positive outcomes could significantly boost the stock by extending the commercial potential of its products and supporting the current valuation. On the other hand, disappointing data could reinforce market skepticism and drive the stock lower.

In addition to clinical progress, potential partnerships or acquisition offers could serve as major value drivers. Given the company’s focus on B-cell malignancies and autoimmune diseases—areas that frequently attract M&A activity—a buyout by a larger pharmaceutical company is a plausible scenario that could deliver immediate value to shareholders.

However, the most pressing operational risk remains the company’s cash position. Rapid expansion and ongoing research require substantial funding, and any signs of financial strain could increase the likelihood of dilutive financing. Investors should closely monitor TG Therapeutics’ balance sheet and cash flow to assess the risk of future capital raises.

Ultimately, the investment case for TG Therapeutics is highly binary in the short term. The company’s fate will be determined by upcoming clinical data and its ability to manage finances responsibly. For those willing to weather volatility and dilution risk, the current share price may offer an attractive entry point into a company with significant long-term potential. Key areas to watch include clinical trial updates, partnership announcements, and the company’s cash burn rate.